Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We recently maintained our Neutral recommendation on biopharmaceutical company, Regeneron Pharmaceuticals (REGN - Analyst Report). Our target price is $195.00 per share.

Why the Reiteration?

Regeneron reported higher-than-expected earnings in the fourth quarter of 2012, on the back of strong sales of its eye-drug Eylea. The drug has performed well since its US launch in late 2011 for treating patients suffering from neovascular form of age-related macular degeneration (wet AMD). The European approval of the drug for the same indication came in Nov 2012.

Sales of Eylea in the US came in at $838 million in 2012, above the company’s projected range of $790–$815 million. Encouraged by the strong performance, the company forecast Eylea sales to increase 50% in 2013 over 2012 levels.

In Sep 2012, the US Food and Drug Administration (FDA) approved the label expansion of Eylea into the macular edema following central retinal vein occlusion (CRVO) indication.

Zaltrap, co-developed with Sanofi (SNY - Analyst Report), is another promising drug in Regeneron’s product portfolio. Zaltrap gained FDA approval in early Aug 2012 for treating previously treated patients suffering from metastatic colorectal cancer. As per Sanofi, sales of Zaltrap were $23 million in the fourth quarter of 2012.

The EU approval of Zaltrap for the same indication in Feb 2013 is another positive for Regeneron. However, we believe that the current price reflects all these positives. Hence, we retain our Neutral recommendation on the stock.

Other Stocks to Consider

The stock carries a Zacks Rank #3 (Hold). Biopharma stocks which appear to be more favorably placed include Athersys Inc. (ATHX - Snapshot Report) and Celgene Corp (CELG - Analyst Report). While Athersys carries a Zacks Rank #1 (Strong Buy), Celgene carries a Zacks Rank #2 (Buy). Both these stocks are worth considering in the biopharma space.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%